Czechia· CZ-0272848
RYSTIGGO
A rozanolixizumab product containing rozanolixizumab, registered in Czechia by UCB Pharma SA, Brusel. The same ATC class is registered in 7 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Rozanolixizumab is registered in 7 of 19 countries.
Countries holding a registration under ATC L04AL02 (rozanolixizumab), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 5 of them publish a price we can compare per daily dose
Rozanolixizumab · ATC L04AL02
7 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- United Kingdom
- United Statesprice
The record
At a glance
SÚKL (Czech Republic)- Active substance
- ROZANOLIXIZUMAB
- Manufacturer
- UCB Pharma SA, Brusel
- Country
- Czechia (CZ)
- ATC code
- L04AL02
- ATC class
- Rozanolixizumab
- Defined daily dose
- 80 mg, P
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Rozanolixizumab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumRystiggo 140 mg/mlUCB Pharma
- SwitzerlandRystiggo 280 mg/2 ml, solution injectableUCB-Pharma SA
- SwedenRystiggo 140 mg/ml Injektionsvätska, lösningUCB Pharma S.A.
- SpainRYSTIGGO 140 MG/ML SOLUCION INYECTABLEUcb Pharma
- IcelandRystiggoUCB Pharma S.A.*
- PolandRystiggoUCB Pharma S.A.
- United StatesRYSTIGGOUCB, Inc.
- United KingdomRystiggo 280mg/2ml solution for injection vialsUCB Pharma Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Rystiggo
- Liechtenstein · Rystiggo
- Norway · Rystiggo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ee20ef93-ba9c-4d30-8f85-654c1d46c386 GET /v1/drugs/ee20ef93-ba9c-4d30-8f85-654c1d46c386?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "INJ SOL",
"source": "sukl",
"strength": "140MG/ML",
"pack_size": "1X3ML",
"substance": "ROZANOLIXIZUMAB",
"cz_kod_sukl": "0272848",
"product_type": "BT",
"substance_codes": "21189",
"registration_state": "R",
"registration_number": "EU/1/23/1780/002"
}See everything about rozanolixizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.